Cellular Uptake of Liposomal Daunorubicin and the Induction of Apoptosis

REFERENCES

• Adler-Moore, J. 1994. AmBisome targeting to fungal infections. Bone Marrow Transplant 14 Suppl 5:S3–S7.
   PubMed Web of Science ®Google Scholar
• Adler-Moore, J. P., Chiang, S. M., Satorius, A., Guerra, D., McAndrews, B., McManus, E. J., and Proffitt, R. T. 1991. Treatment of murine candidosis and cryptococcosi s with a unilamellar liposomal amphoterici n B formulation (AmBisome). J. Antimicrob. Chemother. 28 Suppl B:63-71.
   Google Scholar
• Allen, T. M., Hansen, C. B., and Guo, L. S. 1993. Subcutaneous administration of liposomes: a comparison with the intravenou s and intraperitoneal routes of injection. Biochim. Biophys. Acta 1150:9–16.
   PubMed Web of Science ®Google Scholar
• Arcamone, F., Animati, F., Capranico, G., Lombardi, P., Pratesi, G., Manzini, S., Supino, R., and Zunino, F. 1997. New developments in antitumor anthra-cyclines. Pharmacol. Ther. 76(1-3):117-124.
   Web of Science ®Google Scholar
• Arcamone, F., and Cassinelli, G. 1998. Biosynthetic anthracyclines. Curr. Med. Chem. 5(5):391–419.
   PubMed Web of Science ®Google Scholar
• Arcamone, F. M. 1998. From the pigments of the actinomycetes to third generation antitumor anthracyclines. Biochimie 80(3):201–206.
   PubMed Web of Science ®Google Scholar
• Baselga, J., Norton, L., Albanell, J., Kim, Y. M., and Mendelsohn, J. 1998. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res. 58(13):2825 -2831.
   PubMed Web of Science ®Google Scholar
• Bettaieb, A., Plo, I., Mansat-De Mas, V., Quillet-Mary, A., Levade, T., Laurent, G., and Jaffrezou, J. P. 1999. Daunorubicin- and mitoxantrone-triggered phosphatidylcholine hydrolysis: implication in drug-induced ceramide generation and apoptosis. Mol. Pharmacol. 55(1):118–125.
   PubMed Web of Science ®Google Scholar
• Cabanes, A., Tzemach, D., Goren, D., Horowitz, A. T., and Gabizon, A. 1998. Comparative study of the antitumor activity of free doxorubicin and polyethylene glycol-coated liposomal doxorubicin in a mouse lymphoma model. Clin. Cancer Res. 4(2):499–505.
   PubMed Web of Science ®Google Scholar
• Chaires, J. B. 1998. Drug-DNA interactions. Curr. Opin. Struct. Biol. 8(3):314–320.
   PubMed Web of Science ®Google Scholar
• Cortes, J., Kantarjian, H., O’Brien, S., Giles, F., Koller, C, Beran, M., Keating, M., andEstey, E. 1998. High-dose liposomal daunorubicin (DNX) and Ara-C (HDAC) for refractory or relapsed acute leukaemias: A dose searching study. Blood92: A957.
   Google Scholar
• Dorr, R. T., and Von Hoff, D. D. 1994a. Daunorubicin HCl. In Cancer Chemotherapy Handbook, ed. R. T. Dorr and D. D. Von Hoff. Norwalk, CT: Appleton& Lange.
   Google Scholar
• Dorr, R. T., and Von Hoff, D. D. 1994b. Doxorubicin. In Cancer Chemotherapy Handbook, ed. R. T. Dorr and D. D. Von Hoff. Norwalk, CT: Appleton & Lange.
   Google Scholar
• Forssen, E., Adler-Moore, J., Lee, M. J., Franke, K., McAndrews, B., Oka, M., Toward, M., Krasieva, T, and Tromberg, B. 1996a. In vivo trafficking of daunorubici n liposomes within Kaposi’s sarcoma xenografts (meeting abstract). Proc. Am. Assoc. Cancer Res. 37:A2057 1996.
   Google Scholar
• Forssen, E. A., Coulter, D. M., and Proffitt, R. T. 1992. Selective in vivo localization of daunorubicin small unilamellar vesicles in solid tumors. Cancer Res. 52(12):3255–3261.
   PubMed Web of Science ®Google Scholar
• Forssen, E. A., Male-Brune, R., Adler-Moore, J. P., Lee, M. J., Schmidt, P. G., Krasieva, T. B., Shimizu, S., and Tromberg, B. J. 1996b. Fluorescence imaging studies for the disposition of daunorubici n liposomes (DaunoXome) within tumor tissue. Cancer Res. 56(9):2066–2075.
   PubMed Web of Science ®Google Scholar
• Forssen, E. A., Male-Brune, R., Adler-Moore, J., Lee, M., Frank, K., Dvornikova, T, and Tromberg, B. 1995. In vitro and in vivo fluorescent imaging methods for evaluating the biological disposition of daunorubicin liposomes (DaunoXome) Proc. Am. Assoc. Cancer. Res. 36:A1839 1995.
   Google Scholar
• Forssen E. A., and Ross M. E. 1994. Daunoxome treatment of solid tumors: Preclinical and clinical investigations. J. Liposome Res. 4(1):481–512.
   Google Scholar
• Gabizon, A., Goren, D., Cohen, R., and Barenholz, Y. 1998. Development of liposomal anthracyclines: from basics to clinical applications. J. Cont. Release 53(1–3):275-279.
   Google Scholar
• Gabizon, A., and Martin, F. 1997. Polyethylene glycol-coated (pegylated) liposomal doxorubicin: rationale for use in solid tumours. Drugs 54 Suppl 4:15–21.
   PubMed Web of Science ®Google Scholar
• Gill, P. S., Espina, B. M., Muggia, F., Cabriales, S., Tupule, A., Esplin, J. A., Liebman, H. A., Forssen, E. A., Ross, M. E., and Levine, A. M. 1995. Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin. J. Clin. Oncol. 13:996–1003.
   PubMed Web of Science ®Google Scholar
• Gill, P. S., Wernz, J., Scadden, D. T, Cohen, P., Mukwaya, G. M., Hayden von Roenn, J., Jacobs, M., Kempin, S., Silverberg, I., Gonzales, G., Rarick, M. U., Myers, A. M., Sheperd, F, Sawka, C, Pike, M. C, and, Ross M. E. 1996. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin and vincristine in AIDS-related Kaposi’s sarcoma. J. Clin. Oncol. 14(8):2353–2364.
   Google Scholar
• Goren, D., Horowitz, A. T, Zalipsky, S., Woodle, M. C, Yarden, Y, and Gabizon, A. 1996. Targeting of stealth liposomes to erbB-2 (Her/2) receptor: in vitro and in vivo studies. Br. J. Cancer 74(11):1749–1756.
   PubMed Web of Science ®Google Scholar
• Guaglianone, P., Chan, K., DelaFlor-Weiss, E., Hanisch, R., Jeffers, S., Desh, S., and Muggia, F. 1994. Phase I and pharmacologi c study of liposomal daunorubicin (DaunoXome). Investigational New Drugs 12:103–110.
   PubMed Web of Science ®Google Scholar
• Horowitz, A. T, Barenholz, Y, and Gabizon, A. A. 1992. In vitro cytotoxicity of liposome-encapsulated doxorubicin: Dependence on liposome composition and drug release. Biochim. Biophys. Acta 1109:203–209.
   PubMed Web of Science ®Google Scholar
• James, N. D., Coker, R. J., Tomlinson, D., Harris, J. R. W., Gompels, M., Pinching, A. J., and Stewart, J. S. W. 1994. Liposomal doxorubicin (Doxil): an effective new treatment for Kaposi’s sarcoma in AIDS. Clin. Oncol. (Royal College of Radiologists) 6(5):294–296.
   PubMedGoogle Scholar
• Lasic, D. D., and Papahadjopoulos, D. eds. 1998. Medical Applications of Liposomes. 1st Edition Vol. 1. Amsterdam: Elsevier Science B.V
   Google Scholar
• Malonne, H., and Atassi, G. 1997. DNA topoisomerase targeting drugs: mechanisms of action and perspectives. Anticancer Drugs 8(9):811–822.
   PubMed Web of Science ®Google Scholar
• Martin, F., and Gabizon, A. 1992. Human pharmacokinetic s of Stealth liposomes containing doxorubicin. J. Cell Biochem., Suppl. 16E:94.
   Google Scholar
• McBride, N., Ward, M., Schey, S., Gran, I., Gray, A., Hughes, A., Mills, M., Cavenagh, J., Newland, A., and Kelsey, S. 1998. Liposomal daunorubicin (DaunoXome) in combination with cyclophosphamide, vincristine and prenisolone (COP-X) as salvage therapy in poor-prognosis non-Hodgkin’s lymphoma. Blood 92: A2560.
   Google Scholar
• Papahadjopoulos, D., Allen, T. M., and Gabizon, A. 1991. Sterically stabilised liposomes: improvements in pharmacokinetic s and antitumor therapeutic efficacy. Proc. Natl Acad. Sci. USA 88:11460–11464.
   PubMed Web of Science ®Google Scholar
• Park, J. W., Hong, K., Carter, P., Asgari, H., Guo, L. Y., Keller, G. A., Wirth, C, Shalaby, R., Kotts, C, Wood, W. I., et al. 1995. Development of anti-p185HER2 immunoliposome s for cancer therapy. Proc. Natl. Acad. Sci. USA 92(5):1327–1331.
   PubMed Web of Science ®Google Scholar
• Park, J. W., Hong, K., Kirpotin, D. B., Meyer, O., Papahadjopoulos, D., andBenz, C. C. 1997. Anti-HER2 immunoliposome s for targeted therapy of human tumors. Cancer Lett. 118(2):153–160.
   PubMed Web of Science ®Google Scholar
• Quillet-Mary, A., Mansat, V., Duchayne, E., Come, M. G., Allouche, M., Bailly, J. D., Bordier, C, and Laurent, G. 1996. Daunorubicin-induce d internucle-osomal DNA fragmentation in acute myeloid cell lines. Leukemia 10(3): 417–425.
   PubMed Web of Science ®Google Scholar
• Tritton, T. R. 1991. Cell surface actions of adriamycin. Pharmacol. Ther. 49(3):293–309.
   PubMed Web of Science ®Google Scholar
• Turner, A. F., Presant, C. A., Proffitt, R. T., Williams, L. E., Winsor, D. W, and Werner, J. L. 1988. In-111-labeled liposomes: dosimetry and tumor depiction. Radiology 166:761–765.
   PubMed Web of Science ®Google Scholar
• Vichi, P., Robison, S., and Tritton, T. R. 1989. Temperature dependence of adriamycin-inducedDNAdamageinL1210cells. Cancer Res. 49 (20):5575–5580.
   PubMed Web of Science ®Google Scholar
• Von Hoff, D. D. 1984. Use of daunorubicin in patients with solid tumors. Seminars in Oncology 11 (4):23-27.
   Google Scholar
• Wiles, M. E., Bell, C, Landfair, D., Lynam, E., and Bendele, R. 1997. Anthra-cycline efficacy in vitro: liposomal/non-liposomal daunorubicin (DnR) and doxorubicin (DoX) cytotoxicity for multiple tumor cell types. Drug Delivery 4(4):255–262.
   PubMed Web of Science ®Google Scholar